TT-00973 / TransThera Sciences - LARVOL DELTA

TransThera Wins NMPA Nod for Phase II Lung Cancer Trial of TT-00973 Combo (TipRanks)

New P2 trial • Non Small Cell Lung Cancer

Pharmaron: Reached a cooperation agreement with Allis to jointly advance the Phase II study of TT-00973 in combination with furmonertinib mesylate. [Google translation] (Sohu.com) - "The two parties will jointly conduct a multicenter, open-label Phase II study evaluating the safety and efficacy of TT-00973-MS tablets in combination with firmonertinib mesylate tablets for the treatment of patients with EGFR-sensitive mutation-positive locally advanced or metastatic non-small cell lung cancer. According to the agreement, Pharmaron, as the sponsor of this clinical trial, will bear the operation and costs of the trial. Allis will provide the furmonertinib mesylate tablets required for this clinical trial free of charge. Based on the results of this clinical trial, the two parties will jointly explore opportunities to further collaborate on a Phase III clinical trial of the combination of TT-00973-MS tablets and furmonertinib mesylate tablets."

Licensing / partnership • New P2 trial • Non Small Cell Lung Cancer

TransThera Raises HK$190 Million via H-Share Placing to Fund Tinengotinib Trials and Pipeline R&D (TipRanks) - "TransThera Sciences...is advancing a portfolio of innovative drug candidates centered on its core oncology asset Tinengotinib, alongside other molecules including TT-00973 and TT-01488, targeting specialized treatment needs and reinforcing its presence in the innovative drug development space."

Financing • Oncology

Phase 1 study of TT-00973-MS' a highly selective and potent AXL inhibitor' in patients with advanced solid tumors. (ASCO 2025) - P1 | "The preliminary findings from this phase I study demonstrated that the AXL inhibitor TT-00973-MS monotherapy exhibits a well-tolerable safety profile, promising pharmacodynamic activity, with early signs of efficacy in pts with heavily pre-treated advanced solid tumors. Further studies are warranted to comprehensively evaluate the efficacy and safety of TT-00973-MS in large patient populations and specific tumor types. Clinical trial information: NCT05673538"

Clinical • IO biomarker • Metastases • P1 data • Dyslipidemia • Hypertriglyceridemia • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor • GAS6

TT-00973-MS Tablets in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: TransThera Sciences (Nanjing), Inc.

Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor